SANA Stock Up 53% after 7-Day Win Streak
Sana Biotechnology (SANA) stock hit day 7 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 53% return. The company has gained about $511 Mil in value over the last 7 days, with its current market capitalization at about $962 Mil. The stock remains 156.4% above its value at the end of 2024. This compares with year-to-date returns of 6.4% for the S&P 500.
Comparing SANA Stock Returns With The S&P 500
The following table summarizes the return for SANA stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | SANA | S&P 500 |
|---|---|---|
| 1D | 3.0% | -0.3% |
| 7D (Current Streak) | 53.1% | 0.9% |
| 1M (21D) | 47.7% | 4.2% |
| 3M (63D) | 211.9% | 25.6% |
| YTD 2025 | 156.4% | 6.4% |
| 2024 | -60.0% | 23.3% |
| 2023 | 3.3% | 24.2% |
| 2022 | -74.5% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 42 S&P constituents with 3 days or more of consecutive gains and 50 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 23 | 24 |
| 4D | 15 | 15 |
| 5D | 0 | 4 |
| 6D | 2 | 4 |
| 7D or more | 2 | 3 |
| Total >=3 D | 42 | 50 |
Key Financials for Sana Biotechnology (SANA)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | – | – |
| Operating Income | $-293.1 Mil | $-272.7 Mil |
| Net Income | $-283.3 Mil | $-266.8 Mil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | – | – |
| Operating Income | $-50.9 Mil | $-50.6 Mil |
| Net Income | $-49.1 Mil | $-49.4 Mil |
While SANA stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.